Japanese Consortium Launches Study to Evaluate Utility of Blood-Based Alzheimer's Markers
Shimadzu, Eisai, Oita University, and Usuki City Medical Association are studying the markers in 100 patients using Shimadzu's mass spec technology.
Alzheimer's Drug Discovery Foundation, Pharma Firms Form Biobank Alliance
Roche, Shionogi, Janssen Pharmaceuticals, and Eisai will provide the charity with specimens from Alzheimer's disease patients who participated in clinical studies.
AmoyDx, Eisai Form CDx Development Alliance
Tokyo-based Eisai develops drugs primarily for the neurology and oncology markets, including treatments for Parkinson's disease and breast cancer.